The value of early intervention in RA-a window of opportunity

Clinical Rheumatology

Volumn 30, Issue SUPPL. 1, 2011, Pages

  Breedveld, Ferdinand ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ability to work; Cost effectiveness; Early intervention; Rheumatoid arthritis; Value

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; EARLY INTERVENTION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; WORK CAPACITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 79955586509     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1638-5     Document Type: Review

References (36)

1. KW Drossaers-Bakker M de Buck D van Zeben AH Zwinderman FC Breedveld JM Hazes 1999 Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time Arthritis Rheum 42 1854 1860 10513799 10.1002/1529-0131(199909)42:9<1854:: AID-ANR9>3.0.CO;2-F 1:STN:280:DyaK1MvktF2mtQ%3D%3D (Pubitemid 30257749)
2. J van Aken LR Lard S le Cessie JM Hazes FC Breedveld TW Huizinga 2004 Radiological outcome after 4 years of early vs delayed treatment strategy in patients with recent onset rheumatoid arthritis Ann Rheum Dis 63 274 279 14962962 10.1136/ard.2003.010298 (Pubitemid 38250670)
3. JJ Cush 2007 Early rheumatoid arthritis-is there a window of opportunity? J Rheumatol Suppl 80 1 7 17985417 1:CAS:528:DC%2BD2sXhsVCmsL3I (Pubitemid 350076862)
4. M Benhamou N Rincheval C Roy V Foltz S Rozenberg J Sibilia, et al. 2009 The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort J Rheumatol 36 934 942 19286850 10.3899/jrheum.080762
5. P Emery IB McInnes R van Vollenhoven MC Kraan 2008 Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis Rheumatology 47 392 398 18094000 10.1093/rheumatology/ kem257 1:CAS:528:DC%2BD1cXmslKhtro%3D
6. P Emery 2002 Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes Arthritis Res 4 Suppl 2 S6 S10 12110151 10.1186/ar553
7. JJ Anderson G Wells AC Verhoeven DT Felson 2000 Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration Arthritis Rheum 43 22 29 10643696 10.1002/1529-0131(200001)43:1<22:: AID-ANR4>3.0.CO;2-9 1:STN:280:DC%2BD3c7gs1Cqsg%3D%3D (Pubitemid 30368209)
8. T Möttönen P Hannonen M Korpela M Nissilä H Kautiainen J Ilonen, et al. 2002 Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis Arthritis Rheum 46 894 898 11953964 10.1002/art.10135 (Pubitemid 34303799)
9. D Aletaha J Smolen MM Ward 2006 Measuring function in rheumatoid arthritis: identifying reversible and irreversible components Arthritis Rheum 54 2784 2792 16947781 10.1002/art.22052 (Pubitemid 44497757)
10. M Green H Marzo-Ortega D McGonagle R Wakefield S Proudman P Conaghan J Gooi P Emery 1999 Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope Arthritis Rheum 42 2184 2188 10524691 10.1002/1529-0131(199910)42:10<2184:: AID-ANR20>3.0.CO;2-2 1:STN:280:DyaK1Mvlt1ehsA%3D%3D (Pubitemid 30263603)
11. A Finckh MH Liang CM van Herckenrode P de Pablo 2006 Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis Arthritis Rheum 55 864 872 17139662 10.1002/art.22353 (Pubitemid 44917458)
12. T Mottonen P Hannonen M Leirisalo-Repo M Nissila H Kautiainen M Korpela, et al. 1999 Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial Lancet 353 1568 1573 10334255 10.1016/S0140-6736(98)08513-4 1:CAS:528:DyaK1MXjsFyjsbw%3D (Pubitemid 29219206)
13. M Korpela L Laasonen P Hannonen H Kautiainen M Leirisalo-Repo M Hakala, et al. 2004 Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study Arthritis Rheum 50 2072 2081 15248204 10.1002/art.20351 1:CAS:528:DC%2BD2cXmsVansL0%3D (Pubitemid 38924384)
14. AK Brown PG Conaghan Z Karim MA Quinn K Ikeda CG Peterfy, et al. 2008 An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis Arthritis Rheum 58 2958 2967 18821687 10.1002/art.23945 1:STN:280:DC%2BD1cnkvFeltg%3D%3D
15. P Emery FC Breedveld S Hall P Durez DJ Chang D Robertson A Singh RD Pedersen AS Koenig B Freundlich 2008 Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate-to-severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial Lancet 372 375 382 18635256 10.1016/S0140-6736(08) 61000-4 1:CAS:528:DC%2BD1cXpt1GqtLY%3D
16. MC Genovese JM Bathon RW Martin RM Fleischmann JR Tesser MH Schiff, et al. 2002 Etanercept vs methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes Arthritis Rheum 46 1443 1450 12115173 10.1002/art.10308 1:CAS:528:DC%2BD38Xltlantbk%3D (Pubitemid 34620189)
17. FC Breedveld MH Weisman AF Kavanaugh SB Cohen K Pavelka R van Vollenhoven, et al. 2006 The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate vs methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 26 37 16385520 10.1002/art.21519 1:CAS:528: DC%2BD28XhsVens74%3D (Pubitemid 43122183)
18. P Emery MC Genovese R van Vollenhoven JT Sharp K Patra EH Sasso 2009 Less radiographic progression with adalimumab plus methotrexate vs methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis J Rheumatol 36 1429 1441 19369462 10.3899/jrheum.081018 1:CAS:528:DC%2BD1MXpslemsLY%3D
19. CF Allaart YP Goekoop-Ruiterman JK de Vries-Bouwstra FC Breedveld BA Dijkmans FARR Study Group 2006 Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study Clin Exp Rheumatol 24 6 Suppl 43 S-77 S-82
20. J Kekow RJ Moots P Emery P Durez A Koenig A Singh, et al. 2010 Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial Ann Rheum Dis 69 222 225 19293160 10.1136/ard.2008.102509 1:CAS:528:DC%2BC3cXhtFOlsLw%3D
21. S Yount MV Sorensen D Cella N Sengupta J Grober EK Chartash 2007 Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis Clin Exp Rheumatol 25 838 846 18173917 1:STN:280:DC%2BD1c%2FgvVehsg%3D%3D (Pubitemid 351166434)
22. M Kimel M Cifaldi N Chen D Revicki 2008 Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA J Rheumatol 35 206 215 18085743 1:CAS:528:DC%2BD1cXjtFamsbc%3D (Pubitemid 351284438)
23. National Institute for Health and Clinical Excellence (2007) Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. NICE, London
24. W Burton A Morrison R Maclean E Ruderman 2006 Systematic review of studies of productivity loss due to rheumatoid arthritis Occup Med (Lond) 56 18 27 10.1093/occmed/kqi171 (Pubitemid 43103362)
25. K Puolakka H Kautiainen M Pekurinen T Möttönen P Hannonen M Korpela, et al. 2006 Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial Ann Rheum Dis 65 899 904 16291811 10.1136/ard.2005.045807 1:STN:280:DC%2BD28zlsVKiuw%3D%3D
26. D Lacaille 2005 Arthritis and employment research: where are we? Where do we need to go? J Rheumatol Suppl 72 42 45 15660466 (Pubitemid 40075954)
27. K Puolakka H Kautiainen T Möttönen P Hannonen M Korpela M Hakala, et al. 2005 Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial Arthritis Rheum 52 36 41 15641055 10.1002/art.20716 (Pubitemid 40129230)
28. K Eberhardt BM Larsson K Nived E Lindqvist 2007 Work disability in rheumatoid arthritis-development over 15 years and evaluation of predictive factors over time J Rheumatol 34 481 487 17299844 (Pubitemid 46364001)
29. V Bejarano M Quinn PG Conaghan R Reece AM Keenan D Walker, et al. 2008 Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis Rheum 59 1467 1474 18821658 10.1002/art.24106
30. P Mazonson D Globe C Santas R Murphy A Cheng X Huang, et al. 2008 Assessing the impact of etanercept treatment on productivity: results from a recent RA patient work loss and productivity survey Ann Rheum Dis 67 Suppl II 646
31. A Anis W Zhang P Emery H Sun A Singh B Freundlich R Sato 2009 The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study Rheumatology 48 1283 1289 19690125 10.1093/rheumatology/kep239
32. J Augustsson M Neovius C Cullinane-Carli S Eksborg RF van Vollenhoven 2010 Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry) Ann Rheum Dis 69 126 131 19470527 10.1136/ard.2009.108035 1:CAS:528:DC%2BC3cXhtFOls7o%3D
33. Y Tanaka T Takeuchi T Mimori N Miyasaka T Koike 2009 Discontinuation of infliximab therapy is possible after acquiring remission in patients with rheumatoid arthritis (RA): first report on RRR (remission induction by remicade in RA) study Ann Rheum Dis 68 Suppl 3 120
34. B Saleem S Nizam P Emery 2006 Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 24 Suppl 43 S-33 S-36
35. B Fautrel T Pham G Mouterde X Le Loët P Goupille F Guillemin, et al. 2007 Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis Joint Bone Spine 74 627 637 18037319 10.1016/j.jbspin.2007.10.001 1:CAS:528:DC%2BD1cXitlGku7c%3D (Pubitemid 350236029)
36. WB van den Hout YP Goekoop-Ruiterman CF Allaart JK de Vries-Bouwstra JM Hazes PJ Kerstens, et al. 2009 Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis Arthritis Rheum 61 291 299 19248130 10.1002/art.24169